Vertaling van "its platform for drug " (Frans → Nederlands) :

folding and its platform for drug and target discovery, the company is building a pipeline, initially for neurodegenerative and respiratory conditions. FoldRx’s pipeline includes a program in advanced clinical development to treat genetic neurologic and cardiovascular disorders, Transthyretin (TTR) Amyloid Polyneuropathy (ATTR-PN) and TTR Amyloid Cardiomyopathy (ATTR-CM), and a discovery program in cystic fibrosis, Parkinson’s, and Huntington’s disease based on its broad, proprietary, yeast-based drug discovery platform.

http://www.pfizer.be/sites/be/ (...) (...) [HTML]

FoldRx is a development and discovery company focusing on first-in-class, disease-modifying, small molecule therapeutics to treat diseases of protein misfolding and aggregation (amyloidosis) based on the pioneer work of its scientific founders, Jeffery Kelly (The Scripps Research Institute) and Susan Lindquist (Whitehead Institute).

http://www.pfizer.be/sites/be/ (...) (...) [HTML]

http://www.pfizer.be/sites/be/ (...) [HTML]

Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform ...[+++]

http://www.pfizer.be/sites/be/ (...) (...) [HTML]

This release contains forward-looking information about an agreement by Pfizer to acquire FoldRx, and about FoldRx’s product candidate tafamidis, its other clinical and preclinical development programs and its technology platform, including their potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new ...[+++]

http://www.pfizer.be/sites/be/ (...) (...) [HTML]

http://www.pfizer.be/sites/be/ (...) [HTML]

Wallonie) - PIERLET Mireille (INAMI) - PIETTE Nicolas (Solidaris) - PIRSOUL Bernadette - LUSS - PONCE Annick (SPF Santé Publique) - PONSAERT Frank (NIC - MyCareNet) - QUENNERY Stefanie (Zhapothekers) - QUINET Muriel (SPF Santé Publique) - QUINTIN Emmanuel (eHealth Platform) - QUIRYNEN Vincent (Agoria) - QUOILIN Sophie (WIV-ISP) - RAEYMAEKERS Peter (Zorgnet Vlaanderen) - RAMAECKERS Dirk (ZNA) - RINCHARD Emilie (Coordination bruxelloise d’institutions sociales et de santé) - ROBAYS Hugo (UZ Gent) - ROBBEN Frank (eHealth) - ROEX Ann (Academisch Centrum voor huisartsg ...[+++]

http://www.inami.fgov.be/news/ (...) (...) [HTML]

Wallonie) - PIERLET Mireille (INAMI) - PIETTE Nicolas (Solidaris) - PIRSOUL Bernadette - LUSS - PONCE Annick (SPF Santé Publique) - PONSAERT Frank (NIC - MyCareNet) - QUENNERY Stefanie (Zhapothekers) - QUINET Muriel (SPF Santé Publique) - QUINTIN Emmanuel (eHealth Platform) - QUIRYNEN Vincent (Agoria) - QUOILIN Sophie (WIV-ISP) - RAEYMAEKERS Peter (Zorgnet Vlaanderen) - RAMAECKERS Dirk (ZNA) - RINCHARD Emilie (Coordination bruxelloise d’institutions sociales et de santé) - ROBAYS Hugo (UZ Gent) - ROBBEN Frank (eHealth) - ROEX Ann (Academisch Centrum voor huisartsg ...[+++]

http://www.inami.fgov.be/news/ (...) (...) [HTML]

http://www.inami.fgov.be/news/ (...) [HTML]

- DOGGEN Kris (WIV-ISP) - DUBOULLAY Didier (UC Louvain) - DUPONT François (FIH-W) - DUPONT Yves (WIV-ISP) - DUVILLIER Thibaut (Cabinet Affaires Sociales) - DUYCK Martine (LNZ) - EECKELAERT Arlette (Cerba Medical lab Benelux) - EGGERMONT Rita (Kind en Gezin) - ELIAT-ELIAT Béatrice (MLOZ) - FALEZ Freddy (SPF Affaires Sociales) - FAUQUERT Benjamin (CNPQ - EBMPracticeNet) - FERON Dominique (UNMS) - FIERENS Micky (LUSS) - FIERS Tom (UZ Gent - COZO Vlaanderen) - FORTON Valérie (eHealth Platform) - FREDERICQ Vincent (Femerbel-Ferubel) - GEUD ...[+++]

http://www.inami.fgov.be/news/ (...) (...) [HTML]

- DOGGEN Kris (WIV-ISP) - DUBOULLAY Didier (UC Louvain) - DUPONT François (FIH-W) - DUPONT Yves (WIV-ISP) - DUVILLIER Thibaut (Cabinet Affaires Sociales) - DUYCK Martine (LNZ) - EECKELAERT Arlette (Cerba Medical lab Benelux) - EGGERMONT Rita (Kind en Gezin) - ELIAT-ELIAT Béatrice (MLOZ) - FALEZ Freddy (SPF Affaires Sociales) - FAUQUERT Benjamin (CNPQ - EBMPracticeNet) - FERON Dominique (UNMS) - FIERENS Micky (LUSS) - FIERS Tom (UZ Gent

http://www.inami.fgov.be/news/ (...) (...) [HTML]

http://www.inami.fgov.be/news/ (...) [HTML]

Celle-ci est basée sur les ### [http ...]

http://www.inami.fgov.be/drug/ (...) (...) [HTML]

Dit gebeurt aan de hand van de ### [http ...]

http://www.inami.fgov.be/drug/ (...) (...) [HTML]

http://www.inami.fgov.be/drug/ (...) [HTML]

This release contains forward-looking information about an agreement by Pfizer to acquire FoldRx, and about FoldRx’s product candidate tafamidis, its other clinical and preclinical development programs and its technology platform, including their potential benefits, that involves substantial risks and uncertainties.

http://www.pfizer.be/sites/be/ (...) (...) [HTML]

DISCLOSURE NOTICE: The information contained in this release is as of September 1, 2010. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

http://www.pfizer.be/sites/be/ (...) (...) [HTML]

http://www.pfizer.be/sites/be/ (...) [HTML]

États-Unis, une New Drug Application (NDA) est introduite auprès de la Food and Drug Administration (FDA) américaine.

http://www.pfizer.be/sites/be/ (...) (...) [HTML]

te mogen brengen. In de VS wordt er een New Drug Application (NDA) ingediend bij de Amerikaanse Food and Drug Administration (FDA).

http://www.pfizer.be/sites/be/ (...) (...) [HTML]

http://www.pfizer.be/sites/be/ (...) [HTML]

Aux Etats-Unis, un nouveau traitement peut être lancé immédiatement après son autorisation par la Food and Drug Administration.

http://www.pfizer.be/sites/be/ (...) (...) [HTML]

In de Verenigde Staten kan een nieuw geneesmiddel onmiddellijk na zijn goedkeuring door de Food and Drug Administration gelanceerd worden.

http://www.pfizer.be/sites/be/ (...) (...) [HTML]

http://www.pfizer.be/sites/be/ (...) [HTML]

Une étude récente de la Tufts University démontre que sur les 240 médicaments figurant sur l’Essential Drug List de l’Organisation

http://www.pfizer.be/sites/be/ (...) (...) [HTML]

Een recent verschenen studie van de Tufts University 1 toont aan dat er van de 240 geneesmiddelen op de “Essential Drug List”

http://www.pfizer.be/sites/be/ (...) (...) [HTML]

http://www.pfizer.be/sites/be/ (...) [HTML]

mondiale de la santé, 63 % sont des médicaments « me-too », dont la moitié s’est vu attribuer un rating de priorité par la FDA (Food and Drug Administration) américaine.

http://www.pfizer.be/sites/be/ (...) (...) [HTML]

van de Wereldgezondheidsorganisatie (WGO) 63% opvolggeneesmiddelen zijn, waarvan de helft een prioriteitsstatus van de Amerikaanse FDA (Food and Drug Administration) gekregen hebben.

http://www.pfizer.be/sites/be/ (...) (...) [HTML]

http://www.pfizer.be/sites/be/ (...) [HTML]

Anderen hebben gezocht naar : folding and its platform for drug filed foldrx’s technology platform new drug academisch centrum eggermont rita its technology platform une new drug food and drug l’essential drug its platform for drug

datacenter (12): www.wordscope.be (v4.0.br)

its platform for drug ->

Date index: 2023-06-14